Venus Remedies Limited
Venus Remedies Limited engages in the pharmaceutical business in India and internationally. It is involved in the research and development of solutions focusing on antimicrobial resistance and oncology. The company also offers analgesic, analgesic and antipyretic, antibiotic, anticoagulant, antiemetic, antiviral, cardiovascular, disinfectant and antiseptic, gastro therapy, hepatoprotective, hormo… Read more
Venus Remedies Limited (VENUSREM) - Net Assets
Latest net assets as of September 2025: ₹5.94 Billion INR
Based on the latest financial reports, Venus Remedies Limited (VENUSREM) has net assets worth ₹5.94 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹7.68 Billion) and total liabilities (₹1.74 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹5.94 Billion |
| % of Total Assets | 77.37% |
| Annual Growth Rate | 16.29% |
| 5-Year Change | 40.14% |
| 10-Year Change | 28.18% |
| Growth Volatility | 24.05 |
Venus Remedies Limited - Net Assets Trend (2006–2025)
This chart illustrates how Venus Remedies Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Venus Remedies Limited (2006–2025)
The table below shows the annual net assets of Venus Remedies Limited from 2006 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹5.61 Billion | +15.05% |
| 2024-03-31 | ₹4.88 Billion | +5.91% |
| 2023-03-31 | ₹4.60 Billion | +4.52% |
| 2022-03-31 | ₹4.40 Billion | +10.03% |
| 2021-03-31 | ₹4.00 Billion | +23.79% |
| 2020-03-31 | ₹3.23 Billion | -2.75% |
| 2019-03-31 | ₹3.33 Billion | -8.12% |
| 2018-03-31 | ₹3.62 Billion | -19.86% |
| 2017-03-31 | ₹4.52 Billion | +3.19% |
| 2016-03-31 | ₹4.38 Billion | -4.17% |
| 2015-03-31 | ₹4.57 Billion | -1.07% |
| 2014-03-31 | ₹4.62 Billion | +21.76% |
| 2013-03-31 | ₹3.79 Billion | +23.38% |
| 2012-03-31 | ₹3.07 Billion | +29.70% |
| 2011-03-31 | ₹2.37 Billion | +38.40% |
| 2010-03-31 | ₹1.71 Billion | +23.51% |
| 2009-03-31 | ₹1.39 Billion | +55.75% |
| 2008-03-31 | ₹889.86 Million | +61.41% |
| 2007-03-31 | ₹551.31 Million | +72.85% |
| 2006-03-31 | ₹318.96 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Venus Remedies Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 215266100000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹2.15 Billion | 38.38% |
| Common Stock | ₹133.70 Million | 2.38% |
| Other Comprehensive Income | ₹2.44 Billion | 43.50% |
| Other Components | ₹883.26 Million | 15.75% |
| Total Equity | ₹5.61 Billion | 100.00% |
Venus Remedies Limited Competitors by Market Cap
The table below lists competitors of Venus Remedies Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
RoboRobo Co. Ltd
KQ:215100
|
$67.27 Million |
|
Choil Aluminum
KO:018470
|
$67.33 Million |
|
CAB Payments Holdings Limited
PINK:CABPF
|
$67.33 Million |
|
TigerElec Co. Ltd
KQ:219130
|
$67.36 Million |
|
UBM Development AG
VI:UBS
|
$67.20 Million |
|
Interpark Co. Ltd
KQ:035080
|
$67.19 Million |
|
TOYA S.A. ZY -10
F:6PJ
|
$67.18 Million |
|
Fountaine Pajo
PA:ALFPC
|
$67.17 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Venus Remedies Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,875,501,000 to 5,609,500,000, a change of 733,999,000 (15.1%).
- Net income of 453,200,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 285,648,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹453.20 Million | +8.08% |
| Other Comprehensive Income | ₹285.65 Million | +5.09% |
| Other Changes | ₹-4.85 Million | -0.09% |
| Total Change | ₹- | 15.05% |
Book Value vs Market Value Analysis
This analysis compares Venus Remedies Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.18x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 24.11x to 2.18x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-03-31 | ₹37.94 | ₹914.90 | x |
| 2007-03-31 | ₹65.58 | ₹914.90 | x |
| 2008-03-31 | ₹105.27 | ₹914.90 | x |
| 2009-03-31 | ₹163.96 | ₹914.90 | x |
| 2010-03-31 | ₹202.03 | ₹914.90 | x |
| 2011-03-31 | ₹259.52 | ₹914.90 | x |
| 2012-03-31 | ₹334.34 | ₹914.90 | x |
| 2013-03-31 | ₹388.99 | ₹914.90 | x |
| 2014-03-31 | ₹410.44 | ₹914.90 | x |
| 2015-03-31 | ₹399.10 | ₹914.90 | x |
| 2016-03-31 | ₹381.26 | ₹914.90 | x |
| 2017-03-31 | ₹393.42 | ₹914.90 | x |
| 2018-03-31 | ₹293.26 | ₹914.90 | x |
| 2019-03-31 | ₹269.47 | ₹914.90 | x |
| 2020-03-31 | ₹262.01 | ₹914.90 | x |
| 2021-03-31 | ₹324.33 | ₹914.90 | x |
| 2022-03-31 | ₹329.50 | ₹914.90 | x |
| 2023-03-31 | ₹344.39 | ₹914.90 | x |
| 2024-03-31 | ₹364.74 | ₹914.90 | x |
| 2025-03-31 | ₹419.57 | ₹914.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Venus Remedies Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.08%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.00%
- • Asset Turnover: 0.91x
- • Equity Multiplier: 1.28x
- Recent ROE (8.08%) is below the historical average (14.16%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 50.69% | 19.07% | 1.36x | 1.95x | ₹129.77 Million |
| 2007 | 46.04% | 17.33% | 0.94x | 2.82x | ₹198.70 Million |
| 2008 | 40.24% | 16.40% | 1.05x | 2.34x | ₹269.11 Million |
| 2009 | 31.71% | 16.31% | 0.91x | 2.14x | ₹300.92 Million |
| 2010 | 23.11% | 12.57% | 0.90x | 2.05x | ₹224.41 Million |
| 2011 | 19.51% | 12.69% | 0.79x | 1.95x | ₹225.26 Million |
| 2012 | 15.32% | 11.49% | 0.71x | 1.87x | ₹163.48 Million |
| 2013 | 15.12% | 12.25% | 0.65x | 1.89x | ₹193.97 Million |
| 2014 | 13.93% | 11.99% | 0.64x | 1.81x | ₹181.36 Million |
| 2015 | 1.13% | 1.11% | 0.55x | 1.84x | ₹-405.08 Million |
| 2016 | 0.39% | 0.41% | 0.49x | 1.93x | ₹-420.64 Million |
| 2017 | 1.75% | 2.00% | 0.48x | 1.84x | ₹-372.51 Million |
| 2018 | -8.48% | -8.31% | 0.49x | 2.07x | ₹-668.83 Million |
| 2019 | -8.59% | -9.00% | 0.43x | 2.20x | ₹-618.27 Million |
| 2020 | -3.09% | -2.97% | 0.53x | 1.97x | ₹-423.36 Million |
| 2021 | 15.43% | 11.27% | 0.99x | 1.39x | ₹217.37 Million |
| 2022 | 9.25% | 6.80% | 1.03x | 1.32x | ₹-33.20 Million |
| 2023 | 5.77% | 4.78% | 0.92x | 1.31x | ₹-194.64 Million |
| 2024 | 5.84% | 4.82% | 0.94x | 1.29x | ₹-202.64 Million |
| 2025 | 8.08% | 7.00% | 0.91x | 1.28x | ₹-107.75 Million |
Industry Comparison
This section compares Venus Remedies Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Venus Remedies Limited (VENUSREM) | ₹5.94 Billion | 50.69% | 0.29x | $67.25 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |